Asset Details
Do you wish to reserve the book?
Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers
Do you wish to request the book?
Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers
2025
Overview
Claudin 18.2 (CLDN18.2) has emerged as a highly selective biomarker and its abnormal expression has been reported in various primary malignant tumors. Recently, CLDN18.2 has gained attention as both a prognostic biomarker and a potential therapeutic target in gastric and gastroesophageal junction cancer. The purpose of this study was to investigate CLDN18.2 expression in a large cohort of 168 prostate cancer (PC) tissues, assess its correlation with clinicopathological factors, and evaluate its potential as a therapeutic target for anti-CLDN18.2 therapy.
Immunohistochemical staining was conducted using an approved diagnostic CLDN18.2 immunohistochemistry protocol (Ventana, 43-14A clone). Interpretation was carried out following the general rules for staining evaluation.
Non-neoplastic gastric mucosa, used as a positive control for CLDN18.2 immunostaining, exhibited strong membranous staining. In contrast, no CLDN18.2 expression was detected in normal ductal and acinar cells of prostate tissue, nor in any of the 168 variable PC tissues.
CLDN18.2 is not expressed in normal prostate tissue or PC, suggesting that it is unlikely to serve as a prognostic marker or a potential target for immunotherapy in PC.
Publisher
International Institute of Anticancer Research
